SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 29th, 2020 • Tauriga Sciences, Inc. • Medicinal chemicals & botanical products • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 17, 2020, by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the “Company”), and GS CAPITAL PARTNERS, LLC, with its address at 30 Washington Street, Suite 5L, Brooklyn, NY 11201 (the “Buyer”).
Financing Agreement Supports the Company’s Ongoing Efforts to Develop Pharmaceutical Anti-Nausea ProductFinancing Agreement • January 29th, 2020 • Tauriga Sciences, Inc. • Medicinal chemicals & botanical products
NEW YORK, NY, Jan. 23, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has entered into a $5,000,000 financing agreement with the Tangiers Global, LLC (“Tangiers”) investment fund (“Equity Line” or “Facility”). The $5,000,000 financing is in the form of an Equity Line of Credit over a maximum duration of 36 months (the “Term”). A Form S-1 Registration Statement will be filed with the Securities & Exchange Commission (“SEC”) to register the shares of common stock that may be issued to Tangiers in connection with this this financing. Any issuance of shares of Tauriga’s common stock will be via a Put Notice (“Put”) at the sole discretion of the Company and may be done in varying sized increments ove
